News & Updates

Show Multimedia Only

Hypertension ups risks of adverse outcomes, fibrosis progression in MASLD

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD), who also happen to have hypertension, are at much greater risk of adverse clinical outcomes and progression of liver stiffness and fibrosis, according to a study.

Hypertension ups risks of adverse outcomes, fibrosis progression in MASLD

11 hours ago

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

12 hours ago by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

12 hours ago

Healthy living in early adulthood may prevent steatotic liver disease in midlife

a day ago

Maintaining a healthy lifestyle or making lifestyle changes in early adulthood helps reduce the risk of developing steatotic liver disease in midlife, even for individuals with genetic predisposition, as shown in a study.

Healthy living in early adulthood may prevent steatotic liver disease in midlife

a day ago

Liver supplements popularity on the rise despite limited evidence

03 Feb 2026 by

The market for liver supplements is rapidly growing despite lacking scientific evidence to support their efficacy claims, reveals a study.

Liver supplements popularity on the rise despite limited evidence

03 Feb 2026

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

Patients with hepatocellular carcinoma (HCC) weighing <55 kg who initiate a full dose of lenvatinib tend to lose weight or discontinue treatment, reports a study.

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

Berberine of little benefit in individuals with obesity and MASLD

26 Jan 2026

Treatment with berberine in diabetes-free individuals with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) is safe but falls short of reducing visceral adipose tissue (VAT) and liver fat content, as reported in a study.

Berberine of little benefit in individuals with obesity and MASLD

26 Jan 2026

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026 by

The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026 by

Dietary interventions continue to provide benefits in the management of chronic liver diseases and serve as a valuable addition to pharmacotherapy options available, reports a study.

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026 by

A recent study has demonstrated the long-term safety of mirikizumab in patients with moderate to severe active ulcerative colitis (UC), with no new significant safety concerns.

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

News & Updates

Showing Hepatology articles

Showing

Specialty:

Hypertension ups risks of adverse outcomes, fibrosis progression in MASLD

Hypertension ups risks of adverse outcomes, fibrosis progression in MASLD

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Healthy living in early adulthood may prevent steatotic liver disease in midlife

Healthy living in early adulthood may prevent steatotic liver disease in midlife

Liver supplements popularity on the rise despite limited evidence

Liver supplements popularity on the rise despite limited evidence

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

Berberine of little benefit in individuals with obesity and MASLD

Berberine of little benefit in individuals with obesity and MASLD

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Mediterranean, plant-based diets vital in MASLD management

Mediterranean, plant-based diets vital in MASLD management

Long-term use of mirikizumab does not raise new safety signals

Long-term use of mirikizumab does not raise new safety signals

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients